It sounds counterintuitive, more oxygen calming down an overactive immune system, but that’s exactly what a growing body of immunology research on hyperbaric oxygen therapy (HBOT) suggests.
Rather than simply fueling cells, oxygen tension itself appears to act as a signal that shapes how aggressively the immune system responds. In the context of autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis, HBOT is emerging as a tool that helps shift the balance back toward tolerance in chronic inflammation. The therapy involves increasing oxygen delivery through a pressurized chamber, potentially reducing oxidative stress and modulating cytokines that play a role in immune overactivity.
By targeting cellular repair and tissue oxygenation, HBOT can aid in tissue repair processes, possibly alleviating symptoms in conditions characterized by immune imbalance. As research continues, Hyperbaric Oxygen may become a cornerstone in the management and treatment of autoimmune disorders and related inflammatory conditions.
Hyperbaric oxygen therapy, commonly referred to as HBOT, involves breathing pure oxygen in a pressurized environment, typically within a hyperbaric chamber where the atmospheric pressure is increased to about two to three times the normal level. This unique setting allows the body to absorb oxygen more efficiently, particularly in areas where circulation may be compromised.
Recent research suggests that hyperbaric oxygen therapy (HBOT) may have positive effects on autoimmune conditions by enhancing oxygen delivery and tissue repair.
This process is believed to assist in reducing chronic inflammation and improving immune system balance. Notably, hyperbaric oxygen therapy might lead to a more pronounced reduction in pro-inflammatory cytokines like TNF-α and encourage the production of anti-inflammatory markers and reducing oxidative stress, indicating a stronger systemic anti-inflammatory effect at higher pressures. For more aggressive rheumatic and autoimmune diseases, including lupus and rheumatoid arthritis, research points toward the higher end of that pressure range for meaningful impact.
Overall, however, HBOT shows great promise in symptom suppression for a range of autoimmune disorders that result in chronic pain and inflammation, such as fibromyalgia syndrome, Crohn’s disease, multiple sclerosis, chronic Lyme disease, and more.
A recent narrative review of HBOT’s immunological effects found a consistent pattern across autoimmune and chronic inflammatory disease models: HBOT was associated with expansion of regulatory T cells (the immune system’s “peacekeeper” cells) and suppression of Th17 cell-related inflammatory pathways, a combination that helps recalibrate the immune system toward tolerance rather than ongoing attack. Th17 cells are key inflammatory signals in multiple sclerosis and other autoimmune disorders.
Yes, and this is a key distinction. Multiple hyperbaric oxygen therapy case studies and systematic reviews of research that compare different pressures for HBOT found that 1.3 ATA was effective for modulating mild, low-grade inflammation and oxidative stress, while 2.0 ATA produced a more pronounced reduction in pro-inflammatory cytokines alongside an increase in anti-inflammatory markers, indicating a stronger systemic anti-inflammatory effect at the higher HBOT pressure. For more aggressive inflammatory autoimmune conditions, the research points toward the higher end of that range for meaningful impact.
Preclinical research on the effects of hyperbaric oxygen therapy spans several autoimmune disease models. In lupus-prone mice, early HBOT treatment was shown to reduce the severity of lupus. In models of inflammatory bowel disease, such as Crohn’s Disease and ulcerative colitis, HBOT has been studied with reports of improved symptoms. For instance, cases of Crohn’s disease with perianal and severe perineal presentations showed symptom improvement in several published clinical reports. Additionally, a separate skin-inflammation model utilizing HBOT at 2.5 ATA significantly reduced allergic-inflammation markers (IL-4, IL-5, IgE) and showed a measurable decrease in visible skin ulcers and lesions.
Recent research from Indonesia suggests that HBOT may suppress activation of inflammatory NF-κB signaling pathways and NLRP3 inflammasomes, crucial drivers of chronic inflammatory signaling, while reducing oxidative stress and supporting mitochondrial function in affected tissues. HBOT is also thought to enhance wound-healing and mucosal healing, potentially reshaping gut microbiota composition towards a less inflammatory state, potentially increasing beneficial microbes like Firmicutes and Akkermansia muciniphila. Some studies also indicate that HBOT promotes nitric oxide levels, which can improve angiogenesis and stem cell proliferation, and ultimately boosting tissue repair and cellular metabolism.
It is crucial to clarify that most research on HBOT for autoimmune disorders remains preclinical, involving animal and cell models, with human clinical evidence still forthcoming for most specific conditions. While HBOT has FDA clearance for a list of defined medical indications, autoimmune diseases broadly are not included. However, the existing research supports a plausible rationale for using HBOT as a complementary therapy for managing chronic inflammation under medical supervision, though not as a stand-alone cure or treatment.
The research is fairly clear that pressure level changes in the hyperbaric chamber affects inflammatory pathways and immune cell populations. If your goal is targeting the aggressive inflammatory activity often associated with autoimmune diseases, such as rheumatoid arthritis or lupus, the research points toward the 2.0 ATA+ range. This contrasts with the 1.3 ATA range used in mild wellness chambers. Our Fortius chamber, a hard-shell, hospital-grade hyperbaric oxygen therapy unit reaching 2.0–2.2 ATA, is engineered to operate in that stronger anti-inflammatory range. This setup enhances tissue oxygenation and support for cellular metabolism, fostering cellular repair and reducing oxidative stress effectively.
Managing an autoimmune disorder or chronic inflammatory condition is a long-term commitment. We believe HBOT should be positioned honestly within that management plan, serving as a complementary tool alongside therapies that your rheumatologist, gastroenterologist, or other healthcare providers recommend, not as a replacement. Let’s discuss how HBOT might realistically fit into your treatment regimen, potentially aiding in immune balance, reducing immune overactivity, and supporting overall immune system health through enhanced oxygen delivery and the modulation of cytokines.
HBOT for autoimmune or chronic inflammatory conditions should be discussed with your treating physician. This article summarizes published research, much of it preclinical, for educational purposes and is not medical advice.